Maryann Redlinger

1.8k total citations · 1 hit paper
25 papers, 1.1k citations indexed

About

Maryann Redlinger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maryann Redlinger has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maryann Redlinger's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Maryann Redlinger is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Maryann Redlinger collaborates with scholars based in United States, United Kingdom and China. Maryann Redlinger's co-authors include Peter J. O’Dwyer, Keith T. Flaherty, Marcia S. Brose, Andrea B. Troxel, Laurie A. Loevner, Kanchan Puttaswamy, Anoma Nellore, Susan J. Mandel, Vandana G. Abramson and Lynn M. Schuchter and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Maryann Redlinger

25 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

2008 535 citations Vandana G. Abramson, Andrea B. Troxel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Maryann Redlinger

Since Specialization

Citations

This map shows the geographic impact of Maryann Redlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maryann Redlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maryann Redlinger more than expected).

Fields of papers citing papers by Maryann Redlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maryann Redlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maryann Redlinger. The network helps show where Maryann Redlinger may publish in the future.

Co-authorship network of co-authors of Maryann Redlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Maryann Redlinger. A scholar is included among the top collaborators of Maryann Redlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maryann Redlinger. Maryann Redlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma	Clinical Cancer Research	Naomi B. Haas, Leonard J. Appleman et al.	112
2	Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.	Journal of Clinical Oncology	Mark H. O’Hara, Thomas B. Karasic et al.	24
3	Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer	Cancer	Christine Ciunci, Rodolfo F. Perini et al.	21
4	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study	Cancer Chemotherapy and Pharmacology	Keith T. Flaherty, Chetan Lathia et al.	43
5	Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors	Cancer Research	Kenneth M. Algazy, Lynn M. Schuchter et al.	2
6	Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors	Cancer Chemotherapy and Pharmacology	Crystal S. Denlinger, Rebecca Blanchard et al.	21
7	Effect of BRAF^V600E on response to sorafenib in advanced thyroid cancer patients	Journal of Clinical Oncology	Marcia S. Brose, Andrea B. Troxel et al.	27
8	Phase II Trial of Sorafenib in Advanced Thyroid Cancer breakdown →	Journal of Clinical Oncology	Vandana G. Abramson, Andrea B. Troxel et al.	535
9	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel	Clinical Cancer Research	Keith T. Flaherty, Joan H. Schiller et al.	118
10	A phase II study of sorafenib in metastatic thyroid carcinoma	Journal of Clinical Oncology	Marcia S. Brose, Anoma Nellore et al.	4
11	Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma	Journal of Clinical Oncology	Kanchan Puttaswamy, Wiem Lassoued et al.	13
12	Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis	Journal of Clinical Oncology	Joan H. Schiller, K. T. Flaherty et al.	42
13	A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine	Cancer Chemotherapy and Pharmacology	Keith T. Flaherty, James Stevenson et al.	12
14	Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer	European Journal of Cancer	M L Veronese, James Stevenson et al.	14
15	A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer	Journal of Clinical Oncology	Maryann Redlinger, Amy Kramer et al.	10
16	Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy	Cancer Chemotherapy and Pharmacology	Keith T. Flaherty, James Stevenson et al.	1
17	Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.	PubMed	Weijing Sun, James Stevenson et al.	14
18	Pharmacokinetic (PK)/pharmacodynamic (PD) trial of the new generation platinum compound ZD0473 administered as an iv infusion every 21 days	European Journal of Cancer	James Stevenson, Maryann Redlinger et al.	1
19	Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer	Journal of Clinical Oncology	James Stevenson, Maryann Redlinger et al.	36
20	Irinotecan and UFT/leucovorin in patients with advanced cancers.	PubMed	James Stevenson, Maryann Redlinger et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact